CN114686393B - Bifidobacterium animalis subspecies lactis and composition thereof - Google Patents
Bifidobacterium animalis subspecies lactis and composition thereof Download PDFInfo
- Publication number
- CN114686393B CN114686393B CN202011640744.1A CN202011640744A CN114686393B CN 114686393 B CN114686393 B CN 114686393B CN 202011640744 A CN202011640744 A CN 202011640744A CN 114686393 B CN114686393 B CN 114686393B
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium animalis
- lactis
- bifidobacterium
- subspecies
- animalis subspecies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The application discloses a bifidobacterium animalis subspecies lactis and a composition thereof, belonging to the technical field of biology. The application aims to provide bifidobacterium animalis subspecies which are sensitive to antibiotics, resistant to acid, resistant to bile salts, high in safety and high in stability. The application provides an animal bifidobacterium lactis subspecies (Bifidobacterium animalis subsp.lactis), the strain number is BS-1, the preservation number is CGMCC No.19079, the animal bifidobacterium lactis BS-1 is separated from the feces of infants, and the animal bifidobacterium lactis BS-1 is verified to be sensitive to various antibiotics, has no toxicity, high safety and good storage stability under normal temperature conditions through an antibiotic sensitivity experiment, an acid resistance experiment, a bile salt resistance experiment, a mouse toxicity experiment and a stability experiment, and is suitable for preparing preparations with various dosage forms.
Description
Technical Field
The application belongs to the technical field of biology, and particularly relates to a bifidobacterium animalis subspecies lactis and a composition thereof.
Background
Lactic acid bacteria are a type of probiotics which can grow by utilizing saccharides and produce lactic acid, and have attracted attention because of their beneficial effects of protecting human intestinal health and the like. Lactic acid bacteria include Lactobacillus, bifidobacterium, yeast, etc., and Lactobacillus and Bifidobacterium are widely used in food, pharmaceutical and health product industries. At present, lactobacillus is a group of microorganisms which are widely existing in intestinal tracts of human bodies and are beneficial to host health, and can play roles in maintaining human health, regulating immunity and the like. Specific strains of lactobacillus have been found to colonize the intestinal mucosa and assist in maintaining host health.
At present, a plurality of domestic enterprises utilize animal bifidobacterium lactobacillus subspecies freeze-dried bacterial powder as a raw material to produce biological products, however, the number of viable bacteria of the bacterial powder in the products is a key for evaluating the quality of the probiotic products, and in view of the difference between the characteristics of different animal bifidobacterium lactobacillus subspecies strains, the attenuation of the viable bacteria cannot be effectively prevented by the current products. Therefore, the product can keep enough viable bacteria quantity and prolong the preservation period of the strain so as to fully exert the physiological functions of the strain, reduce the cost and become the technical key for researching and developing viable bacteria preparation products of bifidobacterium animalis subspecies lactis and the application thereof.
Disclosure of Invention
The inventor of the application separates a strain of bacteria from the feces of healthy children, and identifies the strain as bifidobacterium animalis subspecies lactis（Bifidobacterium animalis subsp. lactis）Further, by a series of biochemical experiments, the bacterial strain is found to meet a plurality of indexes of probiotics, so that the inventor unexpectedly isolates a bifidobacterium animalis subspecies which are particularly suitable for being used as probiotics.
The application aims to provide an animal bifidobacterium subspecies which are sensitive to antibiotics, acid-resistant, bile salt-resistant, high in safety and high in stability, and provides an animal bifidobacterium subspecies which are prepared from the animal bifidobacterium subspeciesBifidobacterium animalis subsp. lactis) The bifidobacterium animalis subspecies lactisBifidobacterium animalis subsp. lactis) The sequence of 16S rRNA of the bifidobacterium animalis subspecies lactis BS-1 is shown as SEQ ID NO.1 or has 95 to 99.9 percent of similarity with the SEQ ID NO. 1.
Further defined, the 16S rRNA sequence is shown as SEQ ID NO.1, the preservation number is CGMCC NO.19079, the preservation date is 2019 and 12 months 4, and the animal bifidobacterium subspecies BS-1 is preserved in the China general microbiological culture Collection center with the preservation address of: beijing, chaoyang area, north Chen Xili No.1, 3, china academy of sciences, microbiological institute.
The inventor of the application firstly separates the strain from the feces of healthy children, and identifies the strain as the bifidobacterium animalis subspecies, and further finds that the strain meets a plurality of indexes of probiotics after identifying the biochemical characteristics of the strain, so that the bifidobacterium animalis subspecies can be used as a novel probiotic. Specifically, the inventor finds that the strain is sensitive to various antibiotics, such as penicillin (penicillin, ampicillin, piperacillin), cephalosporins (cefazolin, cefaclor, ceftriaxone, ceftioxime, cefuroxime, ceftazidime), macrolides (erythromycin, azithromycin, clarithromycin), tetracyclines (tetracycline, minocycline, doxycycline), glycopeptides (vancomycin), carbapenems (melonem), rifamycins (rifampin), sulfonamide antibiotics are compound neonomine, chloramphenicol, nitrofurantoin, clindamycin and spectinomycin, and experiments prove that the bifidobacterium lactis of animals have no toxicity to animals such as mice, and the mice survive healthy and normally increase after taking the strain, and meet the quality standard requirements of probiotics; the bifidobacterium animalis subspecies lactis can resist the acidic environment of gastric juice (for example, the survival condition of the strain is good under the artificial gastric juice environment with the pH value of 1.5-4.5); the bifidobacterium animalis subspecies can also resist bile salt environments in intestinal tracts (for example, the bacteria are good in survival state under the condition of 0.03-0.3% of bile salt concentration). The bifidobacterium animalis subspecies can be implanted in human bodies and play a probiotic role. Has better inhibiting effect on harmful flora in intestinal tracts, thereby playing a role in regulating intestinal microbial flora.
According to an embodiment of the present application, the bifidobacterium animalis subspecies lactis may further comprise at least one of the following additional technical features:
it should be noted that the "high acid resistance" in the present application means that the strain still grows and survives well in an acidic environment with a pH as low as 2.5, and the "bile salt resistance" in the present application means that the strain still grows and survives well in an environment with a bile salt concentration as high as 0.3%.
According to the embodiment of the application, the bifidobacterium animalis subspecies lactis has high acid resistance and bile salt resistance, and the bifidobacterium animalis subspecies have good survival conditions under an artificial gastric juice environment with pH of 2.5-4.5 or bile salt concentration of 0.03-0.3%.
Further defined, the bifidobacterium animalis subspecies BS-1 has sensitivity to antibiotics.
Further defined, the antibiotic is a penicillin antibiotic, a cephalosporin antibiotic, a macrolide antibiotic, a tetracycline antibiotic, a glycopeptide antibiotic, a carbapenem antibiotic, a sulfonamide antibiotic, a rifamycin antibiotic, chloramphenicol, nitrofurantoin, clindamycin, and spectinomycin.
Further defined, the penicillin antibiotic is at least one of penicillin, ampicillin, and piperacillin; the cephalosporin antibiotics are at least one of cefazolin, cefaclor, ceftriaxone, cefotaxime, cefuroxime, ceftazidime and cefalotin; the macrolide antibiotic is at least one of erythromycin, azithromycin and clarithromycin; the tetracyclines are at least one of tetracyclines, minocycline and doxycycline; the tetracyclines are at least one of minocycline, tetracycline and doxycycline; the glycopeptides are vancomycin; the carbapenem antibiotic is melopenem; the sulfonamide antibiotics are compound neonomine; the rifamycin antibiotic is rifampicin.
Further defined, the bifidobacterium animalis subspecies BS-1 is resistant to gastric acid.
Further defined, the bifidobacterium animalis subspecies BS-1 is resistant to bile salts.
The application also provides a composition containing the bifidobacterium animalis subspecies lactis, which consists of the bifidobacterium animalis subspecies lactis and pharmaceutically acceptable auxiliary materials.
Further defined, the viable count of the bifidobacterium animalis subspecies lactis is not less than 1X 10 6 cfu/g。
Further defined, the pharmaceutically acceptable excipients are lubricants, fillers, sweeteners, disintegrants.
The beneficial effects are that:
1. the bifidobacterium animalis subspecies BS-1 provided by the application has good acid resistance and bile salt resistance, and can be positioned in a human body to play a probiotic role.
2. The bifidobacterium animalis subspecies BS-1 provided by the application is sensitive to various antibiotics, and the safety of the strain is high.
3. The animal bifidobacterium lactosub-species BS-1 provided by the application has the advantages that the isolated bacteria are fed to mice, so that all the mice are found to be healthy and alive, the weight of the mice is increased normally, and the isolated animal bifidobacterium lactosub-species BS-1 is nontoxic and has high safety.
4. The bifidobacterium animalis subspecies BS-1 provided by the application has good storage stability at normal temperature, and is suitable for preparing probiotic preparations in various dosage forms.
Drawings
FIG. 1 is a photograph of a gram-stained bifidobacterium animalis subspecies lactis BS-1, showing a result of the gram-stained bifidobacterium animalis subspecies BS-1 at a magnification of 100 times;
FIG. 2 is a graph showing the effect of different pH values on the number of viable bacteria of bifidobacterium animalis subspecies BS-1, wherein the abscissa indicates the sampling time and the ordinate indicates the number of viable bacteria;
FIG. 3 is a graph showing the effect of different concentrations of bile salts on the viable count of bifidobacterium animalis subspecies milk BS-1, wherein the abscissa is the sampling time and the ordinate is the viable count;
FIG. 4 shows the stability change of bifidobacterium animalis subspecies BS-1 and commercially available bifidobacterium animalis subspecies MB-1, MB-2 during storage at 20℃for 12 months, wherein the abscissa indicates the sampling time and the ordinate indicates the number of viable bacteria;
FIG. 5 shows the stability change of bifidobacterium animalis subspecies BS-1 and commercial bifidobacterium animalis subspecies MB-1 and MB-2 during storage at 25℃for 12 months, the horizontal axis shows the sampling time and the vertical axis shows the viable count.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The application provides a bifidobacterium animalis subspecies lactis（Bifidobacterium animalis subsp. lactis）The strain number is BS-1, and is preserved in China general microbiological culture Collection center (CGMCC) at 12 months and 4 days in 2019, the preservation address is North Chen Xiyu No.1 and 3 in the Korean region of Beijing city, and the preservation number is CGMCC No.19079.
Balb/c and SPF grade BALB/c mice are commercially available.
Experiment medium: both solid medium TPY and liquid TPY medium were purchased from Qingdao high tech Industrial Yuan Haibo biotechnology Co.
The drug sensitive paper is purchased from Beijing Tiantan Biotechnology development company.
Example 1 isolation, purification and characterization of bifidobacterium animalis subspecies lactis BS-1
Picking up 5-10g of collected fresh feces of healthy infants, filling the feces into a glycerol pipe, and transferring the feces into a refrigerator with a biological ice bag for later use. Transferring anaerobically preserved infant feces sample 1g into 9 ml sterilized normal saline to uniformity, and sequentially performing 10-fold gradient dilution to 1×10 -8 Pipetting 1X 10 with a pipette -6 、1×10 -7 、1×10 -8 3 dilutions were performed in 100 μl each in solid selection medium TPY, 3 plates per dilution. After anaerobic culture at 37 ℃ for 72 hours, bacterial colony with lactobacillus characteristic on the surface is picked, and the single strain is inoculated into TPY culture medium for expansion culture after separation.
Based on the cell morphology shown in FIG. 1, the physiological and biochemical characteristics shown in Table 1 and the comprehensive analysis of 16S rRNA gene sequencing, the isolated strain is identified as a novel bifidobacterium animalis subspecies milk BS-1 by referring to the Bojger' S system bacteriology handbook and International Jouranl of Systematic and Evelutionary Microbiology related research papers.
TABLE 1 physiological and biochemical characteristics of bifidobacterium animalis subspecies lactis BS-1
EXAMPLE 2 antibiotic sensitivity, evaluation of Strain stability and mouse toxicity experiments
2.1 antibiotic susceptibility: the inventors further determined the bifidobacterium animalis subspecies BS-1 strain isolated in example 1 by the K-B method (drug sensitive paper diffusion method) and performed detection of antibiotic susceptibility, and the results showed that bifidobacterium animalis subspecies BS-1 was susceptible to almost all kinds of antibiotics. The results are shown in Table 2.
TABLE 2 antibiotic susceptibility test results of bifidobacterium animalis subspecies lactis BS-1
Remarks: r represents resistance and S represents sensitivity.
2.2 evaluation of stability of strains: by serial subculturing, characteristics such as morphology, physicochemical property and antibiotic susceptibility of the isolated bifidobacterium animalis subspecies BS-1 of example 1 were identified, and no visible change was found in the isolated bifidobacterium animalis subspecies BS-1 after multiple passages, indicating that the isolated bifidobacterium animalis subspecies BS-1 had a stably inheritable shape.
2.3 mouse toxicity experiments:
(1) According to the current edition pharmacopoeia method. The bifidobacterium animalis subspecies BS-1 isolated in example 1 was diluted to 2.0X10 with physiological saline 9 cfu/ml of bacterial suspension, 18-22g of healthy clean-grade Balb/c mice are irrigated, 5 mice in each group are weighed and recorded before the test; each mouse was perfused with 0.5ml of gastric juice 1 time a day for 3 consecutive days, observed day 7 from day 1 lavage, observed for health status of the mice, and recorded for body weight on day 7. The experiment was also set up with a saline control group.
(2) To further investigate the safety of the experimental strain in mice, the intragastric dose used in the reference was taken with a high dose of 10 11 The cfu/ml bacterial liquid is filled into the stomach of Balb/c mice, 10 mice are filled into the stomach of each group, 0.1ml is filled into each mouse, 1 time a day, 8 continuous days, and the appearance is realizedMice were examined for health and changes in body weight were recorded on days 1, 4, and 8. The experiment was performed in a saline control group.
As a result, all mice are found to survive healthily and gain weight normally, which indicates that the isolated bifidobacterium animalis subspecies lactis BS-1 is nontoxic and has high safety.
Example 3 acid and bile salt tolerance experiments of strains
3.1 acid resistance experiments with strains: the artificial gastric juice is prepared according to the current edition pharmacopoeia method. Taking diluted hydrochloric acid 16.4 and ml, adding water about 800 and ml and pepsin 10 and g, shaking uniformly, and adding water to dilute into 1000 and mL to obtain artificial gastric juice. Considering that bacteria enter the stomach in a liquid state and emptying is fast, survival rates within 3 hours are examined in artificial gastric juice. Sampling and counting at 0 min, 15 min, 30 min, 60 min, 90 min, 120 min and 180 min respectively. Taking into account the pH change (1.5-4.5) of the stomach after starvation and meal, sampling and counting at pH of 1.5, 2.5, 3.5 and 4.5 respectively, taking into account the gastric juice at pH of about 2.5 in normal state, and detecting the survival condition of commercial bifidobacterium animalis subspecies MB and bifidobacterium animalis subspecies BS-1 at pH of 1.5-4.5. The results are shown in Table 3 and FIG. 2, and the results show that the bifidobacterium animalis subspecies lactis BS-1 isolated and purified in example 1 has strong acid-resistant activity
TABLE 3 survival of Bifidobacterium animalis subspecies milk BS-1 in artificial gastric juice
Remarks: bifidobacterium lactis subspecies of the present starter: BS-1; commercial bifidobacterium animalis subspecies milk: MB.
3.2 Strain bile salt tolerance experiments: the artificial intestinal juice is prepared according to the current edition pharmacopoeia method. Dissolving potassium dihydrogen phosphate 6.8 and g in 500-ml water, adjusting pH to 6.8 with 0.1 mol/L sodium hydroxide solution, dissolving pancreatin 10g in water, mixing the two solutions, and diluting with water to 1000 ml to obtain artificial intestinal juice. Considering that bacteria enter the small intestine in a liquid state and drain quickly, survival rates within 3 hours are examined in artificial intestinal fluid. Sampling and counting at 0 min, 15 min, 30 min, 60 min, 90 min, 120 min and 180 min respectively. Considering that the content of bile salt in the small intestine of a human body fluctuates within 0.03% -0.3%, respectively designing the bile salt to carry out experiments and sampling counting under the conditions that the mass fractions are 0.03%, 0.1%, 0.2% and 0.3%; considering that bile is in a state of about 0.2% in a usual state, bile is in a state of about 0.3% in an extreme state, and survival of commercial bifidobacterium animalis subspecies MB and bifidobacterium animalis subspecies BS-1 in a state of about 0.03% -0.3% in bile concentration was examined. The results are shown in Table 4 and FIG. 3, and the results show that the bifidobacterium animalis subspecies lactis BS-1 isolated and purified in example 1 has strong cholate resistance.
TABLE 4 survival of Bifidobacterium animalis subspecies milk BS-1 in Artificial intestinal juice
Remarks: the bifidobacterium animalis subspecies of the application: BS-1; commercial bifidobacterium animalis subspecies milk: MB.
EXAMPLE 4 preparation of Bifidobacterium animalis subspecies milk compositions
Preparation of Bifidobacterium animalis subspecies milk BS-1 tablets: the composition containing the bifidobacterium animalis subspecies BS-1 can be prepared into powder, tablets, capsules and drops with pharmaceutically acceptable auxiliary materials, and is prepared into solid preparations, semisolid preparations or liquid preparations, and the embodiment example provides a preparation method of the tablet containing the bifidobacterium animalis subspecies BS-1, which comprises the following steps:
(1) Preparing raw material bacterial powder: activating working seeds of the bifidobacterium animalis subspecies BS-1, culturing the working seeds in a first-stage seed liquid, preparing seeds in a seed tank, fermenting, centrifugally collecting thalli, adding a freeze-drying protective agent, and freeze-drying the thalli to obtain the bifidobacterium animalis subspecies BS-1 bacterial powder.
(2) Pretreatment of raw materials and auxiliary materials: taking Bifidobacterium animalis subspecies BS-1 powder and pharmaceutically acceptable adjuvants such as lubricant (magnesium stearate, talcum powder, polyethylene glycol 6000, stearic acid, sodium/magnesium lauryl sulfate, sodium stearyl fumarate, and glyceryl behenate); glidants (talc, aerosil, silica); fillers (skimmed milk powder, maltodextrin, fructooligosaccharides, pregelatinized starch, lactose, glucose, sucrose, D-mannitol, starch); the sweetener (mannitol, glucose, sucrose, D-mannitol, steviosin, white sugar) is pretreated.
(3) And (2) mixing and preparing: sieving the auxiliary materials with a sieve with the number of 50-200 meshes, adding the auxiliary materials into a batch mixer for uniform mixing, adding the fungus powder for uniform mixing, and discharging after 50 minutes are finished.
(4) And (3) forming: the mixed raw materials and auxiliary materials are transferred into a high-speed tablet press for tabletting, the filling quantity and pressure are regulated in the tabletting process, the weight difference, friability, disintegration degree and the like of the tablet are ensured to meet the quality standard requirements, and the viable count of the final product bifidobacterium animalis subspecies BS-1 is more than or equal to 1 multiplied by 10 6 cfu/g are respectively placed at 4 ℃, 20 ℃ and 25 ℃ for stability investigation, the stability of the bifidobacterium animalis subspecies BS-1 in finished products is determined, and stability investigation results show that the stability of the bifidobacterium animalis subspecies BS-1, the bifidobacterium animalis MB-1 sold in the market and the bifidobacterium animalis MB-2 in the preparation at 4 ℃ are better, the stability is basically not reduced after the preparation is stored for 12 months, and the stability results at 20 ℃ and 25 ℃ are compared with those shown in table 5.
TABLE 5 stability of Bifidobacterium animalis subspecies milk BS-1 and commercial strains in finished products
Remarks: bifidobacterium lactis subspecies of the present starter: BS-1; commercial bifidobacterium animalis subspecies milk: MB-1; commercial bifidobacterium animalis subspecies milk: MB-2.
As shown in Table 5, FIG. 4 and FIG. 5, the stability of the bifidobacterium animalis subspecies BS-1 at 20℃and 25℃was maintained at 1.47E+08cfu/g and 4.90E+07cfu/g, respectively, at 12 months after the production of the final product, whereas the commercial bifidobacterium animalis MB-1 at 20℃was maintained at 4.30E+04cfu/g only and the number of viable bacteria at 25℃was not detected, and the commercial bifidobacterium animalis MB-2 at 20℃was maintained at 4.70E+03cfu/g only and the number of viable bacteria at 25℃was not detected at 12 months after the production of the final product. The stability of the bifidobacterium animalis subspecies BS-1 in the finished product is proved by the stability of the bifidobacterium animalis subspecies BS-1 and commercial strains in the finished product, and is higher than that of the bifidobacterium animalis in the finished product. The bifidobacterium animalis subspecies lactis of the application has better stability in preparing tablets and better stability during 12 months of storage.
SEQUENCE LISTING
<110> Hangzhou far Biopharmaceutical Co Ltd
<120> a bifidobacterium animalis subspecies lactis and compositions thereof
<130>
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 1440
<212> DNA
<213> 16S rRNA
<400> 1
gtcgaacggg atccctggca gcttgctgtc ggggtgagag tggcgaacgg gtgagtaatg 60
cgtgaccaac ctgccctgtg caccggaata gctcctggaa acgggtggta ataccggatg 120
ctccgctcca tcgcatggtg gggtgggaaa tgcttttgcg gcatgggatg gggtcgcgtc 180
ctatcagctt gttggcgggg tgatggccca ccaaggcgtt gacgggtagc cggcctgaga 240
gggtgaccgg ccacattggg actgagatac ggcccagact cctacgggag gcagcagtgg 300
ggaatattgc acaatgggcg caagcctgat gcagcgacgc cgcgtgcggg atggaggcct 360
tcgggttgta aaccgctttt gttcaagggc aaggcacggt ttcggccgtg ttgagtggat 420
tgttcgaata agcaccggct aactacgtgc cagcagccgc ggtaatacgt agggtgcgag 480
cgttatccgg atttattggg cgtaaagggc tcgtaggcgg ttcgtcgcgt ccggtgtgaa 540
agtccatcgc ctaacggtgg atctgcgccg ggtacgggcg ggctggagtg cggtagggga 600
gactggaatt cccggtgtaa cggtggaatg tgtagatatc gggaagaaca ccaatggcga 660
aggcaggtct ctgggccgtc actgacgctg aggagcgaaa gcgtggggag cgaacaggat 720
tagataccct ggtagtccac gccgtaaacg gtggatgctg gatgtggggc cctttccacg 780
ggtcccgtgt cggagccaac gcgttaagca tcccgcctgg ggagtacggc cgcaaggcta 840
aaactcaaag aaattgacgg gggcccgcac aagcggcgga gcatgcggat taattcgatg 900
caacgcgaag aaccttacct gggcttgaca tgtgccggat cgccgtggag acacggtttc 960
ccttcggggc cggttcacag gtggtgcatg gtcgtcgtca gctcgtgtcg tgagatgttg 1020
ggttaagtcc cgcaacgagc gcaaccctcg ccgcatgttg ccagcgggtg atgccgggaa 1080
ctcatgtggg accgccgggg tcaactcgga ggaaggtggg gatgacgtca gatcatcatg 1140
ccccttacgt ccagggcttc acgcatgcta caatggccgg tacaacgcgg tgcgacacgg 1200
tgacgtgggg cggttcgctg aaaaccggtc tcagttcgga tcgcagtctg caactcgact 1260
gcgtgaaggc ggagtcgcta gtaatcgcgg atcagcaacg ccgcggtgaa tgcgttcccg 1320
ggccttgtac acaccgcccg tcaagtcatg aaagtgggta gcacccgaag ccggtggccc 1380
gacccttgtg gggggagccg tctaaggtga gactcgtgat tgggactaag tcgtaacaag 1440
Claims (4)
1. A bifidobacterium animalis subspecies lactis is characterized in thatBifidobacterium animalis subsp. lactis) The animal bifidobacterium subspecies BS-1 is named as BS-1, the preservation number of the animal bifidobacterium subspecies BS-1 is CGMCC NO.19079, and the animal bifidobacterium subspecies BS-1 is preserved in China general microbiological culture collection center with the preservation date of 2019, 12 months and 4 days.
2. A composition comprising the bifidobacterium animalis subspecies lactis of claim 1, wherein the composition is comprised of the bifidobacterium animalis subspecies lactis of claim 1 and pharmaceutically acceptable excipients.
3. The composition according to claim 2, wherein the viable count of bifidobacterium animalis subspecies lactis is not less than 1 x 10 6 cfu/g。
4. The composition according to claim 2, wherein the pharmaceutically acceptable excipients are lubricants, fillers, sweeteners, disintegrants.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011640744.1A CN114686393B (en) | 2020-12-31 | 2020-12-31 | Bifidobacterium animalis subspecies lactis and composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011640744.1A CN114686393B (en) | 2020-12-31 | 2020-12-31 | Bifidobacterium animalis subspecies lactis and composition thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114686393A CN114686393A (en) | 2022-07-01 |
| CN114686393B true CN114686393B (en) | 2023-09-05 |
Family
ID=82136541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011640744.1A Active CN114686393B (en) | 2020-12-31 | 2020-12-31 | Bifidobacterium animalis subspecies lactis and composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114686393B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104498401A (en) * | 2014-12-18 | 2015-04-08 | 杭州龙达新科生物制药有限公司 | Animal bifidobacterium and composition thereof |
| CN104531590A (en) * | 2015-01-14 | 2015-04-22 | 贵州大学 | Fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll |
| CN110037127A (en) * | 2019-04-23 | 2019-07-23 | 彤博士健康产业河北有限公司 | A kind of probiotics preparation and preparation method thereof improving infant's enteron aisle |
| CN110577919A (en) * | 2019-10-14 | 2019-12-17 | 汉臣氏（沈阳）儿童制品有限公司 | heat-resistant bifidobacterium animalis subsp lactis separated from infant feces |
| CN111004735A (en) * | 2019-03-21 | 2020-04-14 | 江南大学 | Lactobacillus fermentum and application thereof in improving intestinal health |
-
2020
- 2020-12-31 CN CN202011640744.1A patent/CN114686393B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104498401A (en) * | 2014-12-18 | 2015-04-08 | 杭州龙达新科生物制药有限公司 | Animal bifidobacterium and composition thereof |
| CN104531590A (en) * | 2015-01-14 | 2015-04-22 | 贵州大学 | Fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll |
| CN111004735A (en) * | 2019-03-21 | 2020-04-14 | 江南大学 | Lactobacillus fermentum and application thereof in improving intestinal health |
| CN110037127A (en) * | 2019-04-23 | 2019-07-23 | 彤博士健康产业河北有限公司 | A kind of probiotics preparation and preparation method thereof improving infant's enteron aisle |
| CN110577919A (en) * | 2019-10-14 | 2019-12-17 | 汉臣氏（沈阳）儿童制品有限公司 | heat-resistant bifidobacterium animalis subsp lactis separated from infant feces |
Non-Patent Citations (1)
| Title |
|---|
| 熊江.动物双歧杆菌乳亚种BZ11、BZ25的性能评价及合生元制备.中国优秀硕士学位论文全文数据库.2018,全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114686393A (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111484957B (en) | Bifidobacterium animalis subsp lactis i797, and separation and purification method and application thereof | |
| CN113088465B (en) | Bifidobacterium lactis strain J605 and application thereof | |
| EP2179028B1 (en) | A novel strain of bifidobacterium and active peptides against rotavirus infections | |
| CN110964655B (en) | Bifidobacterium lactis BL-99 and application thereof | |
| CN113122467B (en) | Lactobacillus paracasei and composition thereof | |
| CN113122466B (en) | Enterococcus faecalis and application thereof | |
| CN116083324B (en) | Bifidobacterium animalis subspecies BA79 capable of improving or treating irritable bowel syndrome and culture method and application thereof | |
| CN114292781B (en) | Bifidobacterium longum SYSU-02 and application thereof | |
| CN116024130A (en) | Lactobacillus fermentum A21215 for reducing blood uric acid and application thereof | |
| CN114107133A (en) | Enterococcus faecium for resisting rectal tumors and application thereof | |
| CN114681493B (en) | Application of bifidobacterium animalis subspecies lactis | |
| CN116254190A (en) | Lactobacillus paracasei subspecies and application thereof | |
| CN116333945B (en) | Helicobacter pylori resistant lactobacillus rhamnosus PUK09 and application, product and method thereof | |
| CN1198631C (en) | Bifidobacteria capable of preventing diarrhea | |
| CN114686393B (en) | Bifidobacterium animalis subspecies lactis and composition thereof | |
| KR20050025002A (en) | Acid tolerant probiotic Lactobacillus reuteri Probio-054 that can suppresses the growth of pathogenic microorganisms | |
| CN113767983A (en) | Human milk freeze-dried powder composition containing infant probiotic bacteria, and preparation method and application thereof | |
| CN116019842B (en) | Antibacterial new application of lactobacillus acidophilus LA85 and application of lactobacillus acidophilus LA85 in preparation of medicines for relieving EIEC diarrhea | |
| CN117305187B (en) | Pediococcus acidilactici for improving intestinal health condition and application thereof | |
| CN117165497B (en) | Lactobacillus plantarum Lp18 for improving constipation, application and product thereof | |
| US20220088092A1 (en) | Compositions and methods for increasing the viability of freeze-dried probiotics | |
| CN117106628B (en) | Lactobacillus acidophilus LA15 with immunoregulation capability and application, product and method thereof | |
| CN117487725B (en) | Lactobacillus acidophilus with immunity regulating effect and application thereof | |
| CN117305189B (en) | Lactobacillus delbrueckii subspecies bulgaricus VB183 and culture device and application thereof | |
| CN115998777B (en) | Use of lactobacillus paracasei 207-27 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |